ACR-7280 / Acrivon Therap - LARVOL DELTA

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 (GlobeNewswire) - "ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models... Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors... Investigational New Drug (IND)-enabling studies are underway, and the company remains on track to submit an IND to the U.S. Food and Drug Administration (FDA) in the first half of 2027... Based on this, initial development will focus on AML, both as single agent and in combination."

IND • Preclinical • Acute Myelogenous Leukemia